Collecting data to predict how metastatic lung cancer will respond to treatment

This research study is collecting blood, urine, and tissue samples from people with metastatic (advanced) lung cancer to build a better understanding of how their cancer responds to standard treatments. Researchers will use computer modeling and biological testing to predict which patients will benefit most from their assigned therapy — whether that's chemotherapy, immunotherapy like pembrolizumab or atezolizumab, or targeted drugs based on specific genetic mutations. The goal is to eventually help doctors personalize treatment plans for future lung cancer patients.

Currently, doctors use standard treatment protocols based on cancer type and genetics, but not all patients respond the same way. This study aims to identify biological patterns that predict treatment response, so that someday doctors can match each patient to the therapy most likely to help them.